The clinician-driven
healthcare investing
platform.

Dental and Oral Care

Though often sequestered off as its own field, oral health is inseparable from overall health. Most oral diseases tend to progress and worsen if untreated. When this happens, patients may find themselves treated in an emergency room for completely preventable issues. In 2018, there were more than 2 million dental-related emergency department visits, at a rate of 615.5 visits per 100,000 population ¹. Finding innovative solutions is key for maturing the dental health market and marrying it with health care as a whole. Studies estimate that over $45 billion is lost in productivity in the United States each year because of untreated oral disease (Harvard Medical School). This is a growing market that is ripe for disruption, and emerging technologies and companies are being built every day to step in and offer solutions. 

(1.https://www.ncbi.nlm.nih.gov/books/NBK574495/)

Maternal Health and Its Future

Maternal health in the U.S. presents a critical investment opportunity as the country grapples with one of the highest maternal mortality rates among developed nations. Startups focused on maternal health, from advanced monitoring technologies to telehealth platforms, are paving the way for safer pregnancies and deliveries. Investing in maternal health truly addresses a pressing public health need.

SAN RAMON, CA, UNITED STATES, September 24, 2024 /EINPresswire.com/ -- Raydiant Oximetry, Inc., a clinical-stage medical device company developing innovations to keep mothers and babies safe during childbirth, has announced the receipt of a $1 million grant from the Bill & Melinda Gates Foundation. The grant will support the development of Raydiant’s Lumerah™ technology, a non-invasive fetal pulse oximeter designed to enhance the detection of fetal distress during childbirth.

In our first episode we were joined by an amazing group of panelists to discuss women’s health and all it encompasses. We touch on topics from barriers to investment and lack of investor understanding, the glaring innovation gap and how it leaves out pregnant women in R&D, the power of partnership between clinicians and investors and so much more.

A huge thank you to panelists from GHIN and our co-investors:
• Sheetal Nariani – General Partner & CFO, Global Health Impact Network & Funds
• Dr. Janet Moore Goldman – Perinatologist, UCSF Health
• Annie Theriault – Managing Partner, Cross-Border Impact Ventures
• Megan Dover, P.Eng., MBA – Junior Partner & Co-founder, Cross-Border Impact Ventures
• Anna Neverova – Founder & CEO, Phi Networks Group

Back to School and Immunizations: Latest News

As the back-to-school season approaches, it's essential to keep up with the latest in pediatric health and immunizations. In honor of National Immunization Awareness Month, this edition of our newsletter provides you with the latest industry news and updates in pediatric immunology and the entire sector. Discover new developments in vaccines, health trends, and how startups of varying sizes are tackling the problem.

Tapping into a trillion dollar opportunity: closing the gender healthcare gap with Raydiant Oximetry

In this issue, we are thrilled to share the remarkable success of our portfolio company, Raydiant Oximetry. The team at Raydiant has raised an oversubscribed Series A extension round with over $7.5 million in funding.

Women’s healthcare is expanding beyond reproductive health to address cardiovascular health, mental health, and chronic conditions, meeting the diverse needs of women throughout their life cycle. AI is revolutionizing the industry, transforming traditional software models and enhancing outcomes through workflow digitization, value-based care, and consumer empowerment.

Raydiant Oximetry, a clinical-stage medical device company focused on improving outcomes for mothers and babies during childbirth has closed an oversubscribed $7.5 million Series A3 extension round.

Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announces that the United States Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for an Early Feasibility Study (EFS) of pregnant women during labor and delivery.